Skip to main content
Premium Trial:

Request an Annual Quote

Quantum Materials, NanoAxis Partner on Microarray, Drug Development

NEW YORK (GenomeWeb News) – Quantum Materials and NanoAxis have forged a deal combining their technologies for diagnostic and pharmaceutical applications.

As part of a deal announced on Wednesday, the two companies will develop quantum dot-based microarray assays for the real-time measurement of cancer biomarkers for research, clinical applications, and product development.

Quantum dots are some of the smallest man-made molecules, the companies said, and their high surface-to-volume ratio provides "excellent" binding affinity for antibodies, peptides, nucleic acids, and other ligands.

Quantum Materials, based in Tempe, Ariz., and NanoAxis, headquartered in Buffalo, NY., will develop new nanomedicine products using Quantum's tetrapod quantum dots and other quantum dot semiconductor nanocrystals to serve as multiplexing platforms for NanoAxis' theranostic therapies in targeting receptors, imaging cells and tissues, and drug delivery of pharmaceutical compounds.

Financial and other terms of the deal were not disclosed.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.